← Back to Clinical Trials
Recruiting NCT07274631

NCT07274631 A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07274631
Status Recruiting
Phase
Sponsor CHU de Reims
Condition Chronic Obstructive Pulmonary Disease
Study Type OBSERVATIONAL
Enrollment 470 participants
Start Date 2025-09-15
Primary Completion 2030-09-15

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Non applicable

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 470 participants in total. It began in 2025-09-15 with a primary completion date of 2030-09-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Chronic inflammatory pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD), bronchiectasis, cystic fibrosis (CF), primary ciliary dyskinesia (PCD) and interstitial lung diseases (ILD) are characterised by lung inflammation and remodelling. Clinical, functional, microbiological, biological, pathological and prognostic features are highly variable and heterogeneous. Several phenotypes have been described within the same pathology, as similar phenotypic traits between different pathologies, or the coexistence of components of several diagnoses in the same patient, suggesting shared underlying mechanisms that could represent new therapeutic targets, beyond the initial medical diagnosis. The objectives of this prospective study are to analyze the phenotypic characteristics (clinical, demographic, biological, morphological, pathological, and microbiological characteristics) together with respiratory exposures and underlying mechanisms involving airway epithelium and inflammation processes in a cohort of patients diagnosed with asthma, COPD, bronchiectasis, CF, PCD and ILD.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years * Follow-up for one of the following conditions: asthma, COPD, bronchiectasis (DDB), cystic fibrosis (CF), primary ciliary dyskinesia (PCD), or interstitial lung diseases (ILD) * Healthy volunteers (controls) Exclusion Criteria: * Subjects protected by law (e.g., legal incapacity) * Any condition preventing informed consent or participation

Contact & Investigator

Central Contact

Jeanne-Marie PEROTIN-COLLARD

✉ jmperotin-collard@chu-reims.fr

📞 03 10 73 67 63

Frequently Asked Questions

Who can join the NCT07274631 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Obstructive Pulmonary Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07274631 currently recruiting?

Yes, NCT07274631 is actively recruiting participants. Contact the research team at jmperotin-collard@chu-reims.fr for enrollment information.

Where is the NCT07274631 trial being conducted?

This trial is being conducted at Reims, France.

Who is sponsoring the NCT07274631 clinical trial?

NCT07274631 is sponsored by CHU de Reims. The trial plans to enroll 470 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology